Genmab A/S of Denmark sharply narrowed its operating loss in 2010 following a reduction in costs and the generation of income from ofatumumab which was given a conditional marketing authorisation in Europe for chronic lymphocytic leukaemia. ---Subscribe to MedNous to access this article--- Company News
